Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients

Journal of Human Hypertension

Volumn 25, Issue 8, 2011, Pages 492-499

  Teixeira, A A ^a   Buffani, A ^a   Tavares, A ^a   Ribeiro, A B ^a   Zanella, M T ^a   Kohlmann, O ^a   Batista, M C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

endothelium drug effects; hydroxymethylglutaryl CoA reductase inhibitors; hypertrophy; insulin resistance; left ventricular; pleiotropism

Indexed keywords

CREATININE; ENALAPRIL; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; ISOSORBIDE MONONITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ARTERY DIAMETER; ARTICLE; BLOOD FLOW; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; ENDOTHELIUM; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEFT VENTRICULAR MASS INDEX; MALE; MICROALBUMINURIA; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL MODEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INDOLES; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 79960464893     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.87     Document Type: Article

References (40)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571-1576. (Pubitemid 26154243)
2. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-1500.
3. Wilhelmsen L, Pyorala K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S): impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001; 22: 1119-1127. (Pubitemid 32666653)
4. Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effects of pravastatin on coronay events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-1009. (Pubitemid 26338729)
6. Schawrtz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Myocardial Ischemia Reduction with Aggressive Cholesterol lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718. (Pubitemid 32259905)
7. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TextCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622. (Pubitemid 28248586)
9. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
10. Calermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adult at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
11. Taylor A, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag 2007; 3: 159-164. (Pubitemid 46860725)
12. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104: 982-985. (Pubitemid 32803872)
13. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44: 904-913. (Pubitemid 39099592)
14. Dechend R, Fielbeler A, Park JK, Muller DN, Theuer J, Mervaala E et al. Amelioration of angiotensin IIinduced cardiac injury by a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Circulation 2001; 104: 576-581. (Pubitemid 32738128)
15. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II induced hypertensive mice. J Cardiovasc Pharmacol 2008; 51: 62-70.
16. Loch D, Levick S, Hoey A, Bronw L. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2006; 47: 396-404. (Pubitemid 44309693)
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 2003. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
18. American Diabetes Association. Standards of medical care in diabetes 2006. Diabetes Care 2006; 29: S4-S85.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
20. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-265.
21. Abetel G, Poget PN, Bonnabry JP. Hypontensive effect of an inhibitor of cholesterol synthesis (fluvastatin): a pilot study. Schweiz Med Wochenschr 1998; 128: 272-277. (Pubitemid 28075465)
22. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002; 16: 705-710. (Pubitemid 35396504)
23. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891-1895. (Pubitemid 27522902)
24. OCallaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG et al. Short term effects of pravastatin on blood pressure in hypercholesterolemic hypertensive patients. Blood Press 1994; 3: 404-406. (Pubitemid 24380427)
25. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramirez JAF. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-1499. (Pubitemid 29228351)
26. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-1286. (Pubitemid 30002395)
27. Terzoli L, Mircoli L, Ferrari AU. Effect of statins on blood pressure (BP) assessed by ambulatory monitoring. J Hypertens 2001; 19: S188.
28. Strazzullo P, Kerry SM, Barbato A, Versiero M, DElia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792-798. (Pubitemid 351664226)
29. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457. (Pubitemid 34225391)
30. Ott C, Schlaich MP, Schmidt BMW, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008; 196: 704-711.
31. Song YS, Manson JE, Tinker L, Howard BV, Kuller LH, Nathan L et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethinc cohort of women. Diabetes Care 2007; 30: 1747-1752. (Pubitemid 47036347)
32. Sari R, Eray E. The effect of atorvastatin treatment on insulin resistance, leptin, and highly sensitive Creactive protein in hypercholesterolemic patients. Endocrinologist 2007; 17: 315-317. (Pubitemid 350307588)
33. Sonmez A, Baykal Y, Kilic M, Yilmaz M, Saglam K, Bulucu F et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003; 22: 151-154.
34. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacol 2004; 58: 614-618. (Pubitemid 40260386)
35. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362. (Pubitemid 32105973)
36. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
37. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55: 1209-1216.
38. Cirrincione GM, Boluyt MO, Hwang HS, Bleske BE. 3-HMG-Coenzyme A reductase inhibitor and extracellular matrix gene expression in the pressure-overloaded rat heart. J Cardiovasc Pharmacol 2006; 47: 521-530. (Pubitemid 44309670)
39. De Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33: 473-478. (Pubitemid 29101992)
40. Colquhoun D, Jackson R, Walters M, Hicks B, Goldsmith J, Young P et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans. Eur J Clin Invest 2005; 35: 251-258. (Pubitemid 40546923)